A press release has been issued by Satsuma Pharmaceuticals, Inc.
- Business
Announcement Date: June 1, 2020 (U.S. Time)
detail:
It was announced that the enrollment of 1,140 participants in the Phase 3 clinical efficacy trial (EMERGE) for the nasal migraine medication STS101, which is being developed by Satsuma Pharmaceuticals, Inc., has been completed.
For more details Here please refer to the original press release.